The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Official Title: A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Study ID: NCT03822468
Brief Summary: QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib. The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing regimen of 400 mg ribociclib orally QD 3 weeks on/1 week off may decrease the risk of QTc prolongation without compromising the efficacy of ribociclib in combination with a non-steroidal aromatase inhibitor (NSAI) in pre- and postmenopausal women with hormone receptor-positive (HR-positive), HER2-negative advanced breast cancer (aBC) who have not received prior therapy for advanced disease.
Detailed Description: This is a phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of a reduced ribociclib dose of 400 mg in combination with an NSAI (letrozole or anastrozole) for the treatment of pre- and postmenopausal women with HR-positive, HER2-negative aBC who have received no prior therapy for advanced disease. Patients will be randomly assigned to one of the below treatment arms in a 1:1 ratio: * Experimental arm - Ribociclib 400 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women) * Control arm - Ribociclib 600 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women). Participants will receive study treatment until disease progression (radiologically documented according to RECIST 1.1 criteria), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. Continuation of study treatment beyond initial disease progression (RECIST 1.1) will not be allowed. For participants who discontinue treatment for reasons other than documented disease progression, death, lost to follow-up, or withdrawal of consent, tumor assessments must continue to be performed until disease progression, death, lost to follow-up, or withdrawal of consent (post-treatment efficacy follow-up).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Southern Cancer Center PC ., Mobile, Alabama, United States
Marin Cancer Care, Greenbrae, California, United States
Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Longmont, Colorado, United States
Florida Retina Institute, Orlando, Florida, United States
Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States
Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States
Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Henderson, Nevada, United States
New York Oncology Hematology SC, Albany, New York, United States
Montefiore Medical Center, Bronx, New York, United States
Mount Sinai School of Medicine CFTY720D2306, New York, New York, United States
Millennium Research Clin Develop ., Houston, Texas, United States
Texas Oncology, McAllen, Texas, United States
Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States
Novartis Investigative Site, San Juan, , Argentina
Novartis Investigative Site, Innsbruck, , Austria
Novartis Investigative Site, Linz, , Austria
Novartis Investigative Site, Salzburg, , Austria
Novartis Investigative Site, Vienna, , Austria
Novartis Investigative Site, Edegem, Antwerpen, Belgium
Novartis Investigative Site, Namur, , Belgium
Novartis Investigative Site, Goiania, GO, Brazil
Novartis Investigative Site, Natal, RN, Brazil
Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Sao Jose do Rio Preto, , Brazil
Novartis Investigative Site, Plovdiv, , Bulgaria
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Sofia, , Bulgaria
Novartis Investigative Site, Cambridge, Ontario, Canada
Novartis Investigative Site, Valledupar, Cesar, Colombia
Novartis Investigative Site, Ibague, Tolima, Colombia
Novartis Investigative Site, Bogota, , Colombia
Novartis Investigative Site, Bogota, , Colombia
Novartis Investigative Site, Monteria, , Colombia
Novartis Investigative Site, San Jose, , Costa Rica
Novartis Investigative Site, Brno, Czech Republic, Czechia
Novartis Investigative Site, Praha 5, , Czechia
Novartis Investigative Site, Helsinki, , Finland
Novartis Investigative Site, Tampere, , Finland
Novartis Investigative Site, Besancon Cedex, , France
Novartis Investigative Site, Caen, , France
Novartis Investigative Site, Clermont Ferrand, , France
Novartis Investigative Site, Lyon Cedex 08, , France
Novartis Investigative Site, Marseille, , France
Novartis Investigative Site, Montpellier, , France
Novartis Investigative Site, Saint Herblain, , France
Novartis Investigative Site, Strasbourg, , France
Novartis Investigative Site, Valenciennes, , France
Novartis Investigative Site, Langen, Hessen, Germany
Novartis Investigative Site, Augsburg, , Germany
Novartis Investigative Site, Berlin, , Germany
Novartis Investigative Site, Bonn, , Germany
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Tuebingen, , Germany
Novartis Investigative Site, Weiden, , Germany
Novartis Investigative Site, Budapest, , Hungary
Novartis Investigative Site, Debrecen, , Hungary
Novartis Investigative Site, Szolnok, , Hungary
Novartis Investigative Site, Raipur, Chhattisgarh, India
Novartis Investigative Site, Nagpur, Maharashtra, India
Novartis Investigative Site, Bhubaneshwar, Orissa, India
Novartis Investigative Site, Delhii, , India
Novartis Investigative Site, Mumbai, , India
Novartis Investigative Site, Amman, , Jordan
Novartis Investigative Site, Kaunas, LTU, Lithuania
Novartis Investigative Site, Vilnius, , Lithuania
Novartis Investigative Site, Trujillo, La Libertad, Peru
Novartis Investigative Site, San Borja, Lima, Peru
Novartis Investigative Site, San Isidro, Lima, Peru
Novartis Investigative Site, San Miguel, Lima, Peru
Novartis Investigative Site, Lisbon, , Portugal
Novartis Investigative Site, Loures, , Portugal
Novartis Investigative Site, Porto, , Portugal
Novartis Investigative Site, Arkhangelsk, , Russian Federation
Novartis Investigative Site, Moscow, , Russian Federation
Novartis Investigative Site, Moscow, , Russian Federation
Novartis Investigative Site, St Petersburg, , Russian Federation
Novartis Investigative Site, St Petersburg, , Russian Federation
Novartis Investigative Site, Cape Town, , South Africa
Novartis Investigative Site, Johannesburg, , South Africa
Novartis Investigative Site, Parktown, , South Africa
Novartis Investigative Site, Stockholm, , Sweden
Novartis Investigative Site, Stockholm, , Sweden
Novartis Investigative Site, Uppsala, , Sweden
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Chiang Mai, , Thailand
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR